Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication

Cancer

Volumn 116, Issue 7, 2010, Pages 1827-1837

  Siena, Salvatore ^a   Glynne Jones, Robert ^b   Adenis, Antoine ^c   Thaler, Josef ^d   Preusser, Peter ^e   Aguilar, Enrique Aranda ^f   Aapro, Matti S ^g   Loos, Anja H ^h   Esser, Regina ^h   Wilke, Hansjochen ⁱ  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

^c CENTRE OSCAR LAMBRET   (France)

^d Kreuzschwestern Wels Clinic   (Austria)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^f HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^g CLINIQUE DE GENOLIER   (Switzerland)

^h MERCK KGAA   (Germany)

ⁱ Klinikum Essen Mitte   (Germany)

Author keywords

Epidermal growth factor receptor; Hypersensitivity; MABEL; Monoclonal antibody; Prophylaxis

Indexed keywords

ALIZAPRIDE; ANTIHISTAMINIC AGENT; BUDESONIDE; CETIRIZINE; CETUXIMAB; CHLORPHENIRAMINE; CLEMASTINE; CORTICOSTEROID; DEXAMETHASONE; DEXCHLORPHENIRAMINE; DIMETINDENE; DIPHENHYDRAMINE; HYDROCORTISONE; IRINOTECAN; MEPREDNISONE; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; PROMETHAZINE;

ADULT; AGED; ANAPHYLACTIC SHOCK; ANAPHYLAXIS; ANGINA PECTORIS; ARTICLE; ASTHMA; BRONCHOSPASM; CHILL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYANOSIS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPNEA; FEMALE; FEVER; HEART INFARCTION; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; OVERALL SURVIVAL; POST HOC ANALYSIS; PRACTICE GUIDELINE; PREMEDICATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESPIRATORY FAILURE; SYNCOPE; TREATMENT FAILURE;

ADRENAL CORTEX HORMONES; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; HYPERSENSITIVITY; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PREMEDICATION; RETREATMENT;

EID: 77950196196     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24945     Document Type: Article

References (33)

1. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006;6:714-727.
2. Zafir-Lavie I, Michaeli Y, Reiter Y. Novel antibodies as anti-cancer agents. Oncogene. 2007;26:3714-3733.
3. Hewitt MR, Sun W. Oxaliplatin-associated hypersensitivity reactions: clinical presentation and management. Clin Colorectal Cancer. 2006;6:114-117.
4. Navo M, Kunthur A, Badell ML, et al. Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients. Gynecol Oncol. 2006;103:608-613.
5. Hennenfent KL, Govindan R. Novel formulations of taxanes: a review. Old wine in a new bottle? Ann Oncol. 2006;17:735-749.
6. Fumoleau P, Coudert B, Isambert N, Ferrant E. Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol. 2007;18(suppl 5):v9-15.
7. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist. 2007;12:601-609.
8. Weiss RB. Hypersensitivity reactions. Semin Oncol. 1992;19:458-477.
9. Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist. 2008;13:725-732.
10. Bibeau F, Lopez-Crapez E, Di Fiore F, et al. Impact of FcγRIIa-FcγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol. 2009;27:1122-1129.
11. Kurai J, Chikumi H, Hashimoto K, et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res. 2007;13:1552-1561.
12. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell. 2005;7:301-311.
13. Zhang W, Gordon M, Schultheis AM, et al. Two immunoglobulin G fragment C receptor polymorphisms associated with clinical outcome of EGFR-expressing metastatic colorectal cancer patients treated with single agent cetuximab [abstract]. J Clin Oncol. 2006;24:(suppl 18). Abstract 3028.
14. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345.
15. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357:2040-2048.
16. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:2311-2319.
17. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408-1417.
18. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27:663-671.
19. ERBITUX. Summary of product characteristics. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/erbitux/H-558-PI-en.pdf. Accessed July 14, 2009.
20. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25:2171-2177.
21. Wilke H, Glynne-Jones R, Thaler J, et al. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study. J Clin Oncol. 2008;26:5335-5343.
22. Patel DD, Goldberg RM. Cetuximab-associated infusion reactions: pathology and management. Oncology (Williston Park). 2006;20:1373-1382; See discussion 2006;20:1382, 1392-1374, 1397.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
24. Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics. 1982;38:29-41.
25. Cox DR. Regression models and life tables (with discussion). Journal of Royal Statistical Society: Series B. 1972; 34:187-220.
26. Giusti RM, Shastri KA, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: panitumumab (Vectibix). Oncologist. 2007;12:577-583.
27. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009;27:672-680.
28. Pfeiffer P, Nielsen D, Bjerregaard J, Qvortrup C, Yilmaz M, Jensen B. Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Ann Oncol. 2008;19:1141-1145.
29. Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol. 2001;19:3234-3243.
30. Timoney J, Chung KY, Park V, Trocola R, Peake C, Saltz LB. Cetuximab use without chronic antihistamine premedication [abstract]. J Clin Oncol. 2006;24:(suppl 18). Abstract 13521.
31. Needle MN. Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody. Semin Oncol. 2002;29:55-60.
32. O'Neil BH, Allen R, Spigel DR, et al. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol. 2007;25:3644-3648.
33. Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 2008;358:1109-1117.